Skip to main content
Erschienen in: Journal of Inherited Metabolic Disease 2/2011

01.04.2011 | Rapid Communication

Evaluation of high density lipoprotein as a circulating biomarker of Gaucher disease activity

verfasst von: Philip Stein, Ruhua Yang, Jun Liu, Gregory M. Pastores, Pramod K. Mistry

Erschienen in: Journal of Inherited Metabolic Disease | Ausgabe 2/2011

Einloggen, um Zugang zu erhalten

Abstract

Circulating biomarkers are important surrogates for monitoring disease activity in type I Gaucher disease (GD1). We and others have reported low high-density lipoprotein (HDL) in GD1. We assessed HDL cholesterol as a biomarker of GD1, with respect to its correlation with indicators of disease severity and its response to imiglucerase enzyme replacement therapy (ERT). In 278 consecutively evaluated GD1 patients, we correlated HDL cholesterol, chitotriosidase, and angiotensin-converting enzyme (ACE) with indicators of disease severity. Additionally, we measured the response of these biomarkers to ERT. HDL cholesterol was negatively correlated with spleen volume, liver volume, and GD severity score index; the magnitude of this association of disease severity with HDL cholesterol was similar to that for ACE and for chitotriosidase. Within individual patients monitored over many years, there was a strikingly strong correlation of HDL with liver and spleen volumes; there was a similarly strong correlation of chitotriosidase and ACE with disease severity in individual patients monitored serially over many years (chitotriosidase r = 0.96 to 0.98, ACE r  = 0.88 to 0.94, and HDL r = −0.84 to −0.94, p < 0.001). ERT for 3 years resulted in a striking increase of HDL while serum levels of chitotriosidase and ACE decreased. Our results reveal markedly low HDL cholesterol in untreated GD1, a correlation with indicators of disease severity in GD1, and a rise towards normal after ERT. These findings suggest HDL cholesterol merits inclusion within the “biomarker basket” for monitoring of patients with GD1.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
Zurück zum Zitat Aerts JMFG, Hollak CEM, van Breemen M, Maas M, Groener JEM, Boot R (2005) Identification and use of biomarkers in Gaucher disease and other lysosomal storage diseases. Acta Paediatr 94:43–46CrossRef Aerts JMFG, Hollak CEM, van Breemen M, Maas M, Groener JEM, Boot R (2005) Identification and use of biomarkers in Gaucher disease and other lysosomal storage diseases. Acta Paediatr 94:43–46CrossRef
Zurück zum Zitat Aguilera B, Ghauharali-Van Der Vlugt K, Helmond MT et al (2003) Transglycosidase activity of chitotriosidase: improved enzymatic assay for the human macrophage chitanase. J Biol Chem 278:4091–4096CrossRef Aguilera B, Ghauharali-Van Der Vlugt K, Helmond MT et al (2003) Transglycosidase activity of chitotriosidase: improved enzymatic assay for the human macrophage chitanase. J Biol Chem 278:4091–4096CrossRef
Zurück zum Zitat Barton NW, Brady RO, Dambrosia JM et al (1991) Replacement therapy for inherited enzyme deficiency—macrophage-targeted glucocerebrosidase for Gaucher's disease. N Engl J Med 324:1464–1470PubMedCrossRef Barton NW, Brady RO, Dambrosia JM et al (1991) Replacement therapy for inherited enzyme deficiency—macrophage-targeted glucocerebrosidase for Gaucher's disease. N Engl J Med 324:1464–1470PubMedCrossRef
Zurück zum Zitat Berger J, Lecourt S, Vanneaux V et al (2010) Glucocerebrosidase deficiency dramatically impairs human bone marrow haematopoiesis in an in vitro model of Gaucher disease. Br J Haematol 150:93–101PubMed Berger J, Lecourt S, Vanneaux V et al (2010) Glucocerebrosidase deficiency dramatically impairs human bone marrow haematopoiesis in an in vitro model of Gaucher disease. Br J Haematol 150:93–101PubMed
Zurück zum Zitat Boot RG, Renkema GH, Verhoek M et al (1998) The human chitotriosidase gene. Nature of inherited enzyme deficiency. J Biol Chem 273:25680–25685PubMedCrossRef Boot RG, Renkema GH, Verhoek M et al (1998) The human chitotriosidase gene. Nature of inherited enzyme deficiency. J Biol Chem 273:25680–25685PubMedCrossRef
Zurück zum Zitat Boot RG, Verhoek M, De Fost M et al (2004) Marked elevation of the chemokine CCL18/PARC in Gaucher disease: a novel surrogate marker for assessing therapeutic intervention. Blood 103:33–39PubMedCrossRef Boot RG, Verhoek M, De Fost M et al (2004) Marked elevation of the chemokine CCL18/PARC in Gaucher disease: a novel surrogate marker for assessing therapeutic intervention. Blood 103:33–39PubMedCrossRef
Zurück zum Zitat Boot RG, van Breemen MJ, Wegdam W et al (2009) Gaucher disease: a model disorder for biomarker discovery. Expert Rev Proteomics 6:411–419PubMedCrossRef Boot RG, van Breemen MJ, Wegdam W et al (2009) Gaucher disease: a model disorder for biomarker discovery. Expert Rev Proteomics 6:411–419PubMedCrossRef
Zurück zum Zitat Boven LA, van Meurs M, Boot RG et al (2004) Gaucher cells demonstrate a distinct macrophage phenotype and resemble alternatively activated macrophages. Am J Clin Pathol 122:359–369PubMedCrossRef Boven LA, van Meurs M, Boot RG et al (2004) Gaucher cells demonstrate a distinct macrophage phenotype and resemble alternatively activated macrophages. Am J Clin Pathol 122:359–369PubMedCrossRef
Zurück zum Zitat Bussink AP, Van Eijk M, Renkema GH et al (2006) The biology of the Gaucher cell: the cradle of human chitinases. Int Rev Cytol 252:71–128PubMedCrossRef Bussink AP, Van Eijk M, Renkema GH et al (2006) The biology of the Gaucher cell: the cradle of human chitinases. Int Rev Cytol 252:71–128PubMedCrossRef
Zurück zum Zitat Cenarro A, Pocovi M, Giraldo P, Garcia-Otin AL, Ordovas JM (1999) Plasma lipoprotein responses to enzyme replacement in Gaucher’s disease. Lancet 353:642–643PubMedCrossRef Cenarro A, Pocovi M, Giraldo P, Garcia-Otin AL, Ordovas JM (1999) Plasma lipoprotein responses to enzyme replacement in Gaucher’s disease. Lancet 353:642–643PubMedCrossRef
Zurück zum Zitat Chupp GL, Lee CG, Jarjour N et al (2007) A chitanase-like protein in the lung and circulation of patients with severe asthma. N Engl J Med 357:2016–2027PubMedCrossRef Chupp GL, Lee CG, Jarjour N et al (2007) A chitanase-like protein in the lung and circulation of patients with severe asthma. N Engl J Med 357:2016–2027PubMedCrossRef
Zurück zum Zitat Clarke JTR (1981) The glycosphingolipids of human plasma lipoproteins. Can J Biochem 59:412–417PubMedCrossRef Clarke JTR (1981) The glycosphingolipids of human plasma lipoproteins. Can J Biochem 59:412–417PubMedCrossRef
Zurück zum Zitat Cox TM (2010) Eliglustat tartrate, an orally active glucocerebroside synthase inhibitor for the potential treatment of Gaucher disease and other lysosomal storage diseases. Curr Opin Investig Drugs 11:1169–1181PubMed Cox TM (2010) Eliglustat tartrate, an orally active glucocerebroside synthase inhibitor for the potential treatment of Gaucher disease and other lysosomal storage diseases. Curr Opin Investig Drugs 11:1169–1181PubMed
Zurück zum Zitat Deegan PB, Moran MT, McFarlane I, Schofield JP, Boot RG, Aerts JMFG, Cox TM (2005) Clinical evaluation of chemokine and enzymatic biomarkers of Gaucher disease. Blood Cells Mol Dis 35:259–267PubMedCrossRef Deegan PB, Moran MT, McFarlane I, Schofield JP, Boot RG, Aerts JMFG, Cox TM (2005) Clinical evaluation of chemokine and enzymatic biomarkers of Gaucher disease. Blood Cells Mol Dis 35:259–267PubMedCrossRef
Zurück zum Zitat De Fost M, Langeveld M, Franssen R et al (2009) Low HDL cholesterol level in type I Gaucher disease do not lead to an increased risk of cardiovascular disease. Atherosclerosis 204:267–272PubMedCrossRef De Fost M, Langeveld M, Franssen R et al (2009) Low HDL cholesterol level in type I Gaucher disease do not lead to an increased risk of cardiovascular disease. Atherosclerosis 204:267–272PubMedCrossRef
Zurück zum Zitat Ghauharali-van der Vlugt K, Langeveld M, Poppema A (2008) Prominent increase in plasma ganglioside GM3 is associated with clinical manifestations of type I Gaucher disease. Clin Chim Acta 389:109–113PubMedCrossRef Ghauharali-van der Vlugt K, Langeveld M, Poppema A (2008) Prominent increase in plasma ganglioside GM3 is associated with clinical manifestations of type I Gaucher disease. Clin Chim Acta 389:109–113PubMedCrossRef
Zurück zum Zitat Ginsberg H, Grabowski GA, Gibson JC, Fagerstrom R, Goldblatt J, Gilbert HS, Desnick RJ (1984) Reduced plasma concentrations of total, low density lipoprotein and high density lipoprotein cholesterol in patients with Gaucher type I disease. Clin Genet 26:109–116PubMedCrossRef Ginsberg H, Grabowski GA, Gibson JC, Fagerstrom R, Goldblatt J, Gilbert HS, Desnick RJ (1984) Reduced plasma concentrations of total, low density lipoprotein and high density lipoprotein cholesterol in patients with Gaucher type I disease. Clin Genet 26:109–116PubMedCrossRef
Zurück zum Zitat Grabowski GA (2008) Phenotype, diagnosis, and treatment of Gaucher's disease. Lancet 372:1263–1271PubMedCrossRef Grabowski GA (2008) Phenotype, diagnosis, and treatment of Gaucher's disease. Lancet 372:1263–1271PubMedCrossRef
Zurück zum Zitat Groener JE, Poorthuis BJ, Kuiper S, Hollak CE, Aerts JM (2008) Plasma glucosylceramide and ceramide in type 1 Gaucher disease patients: correlations with disease severity and response to therapeutic intervention. Biochim Biophys Acta 1781:72–78PubMed Groener JE, Poorthuis BJ, Kuiper S, Hollak CE, Aerts JM (2008) Plasma glucosylceramide and ceramide in type 1 Gaucher disease patients: correlations with disease severity and response to therapeutic intervention. Biochim Biophys Acta 1781:72–78PubMed
Zurück zum Zitat Hollak CE, van Weely S, van Oers MH, Aerts JM (1994) Marked elevation of plasma chitrotriosidase activity. A novel hallmark of Gaucher disease. J Clin Invest 93:1288–1292PubMedCrossRef Hollak CE, van Weely S, van Oers MH, Aerts JM (1994) Marked elevation of plasma chitrotriosidase activity. A novel hallmark of Gaucher disease. J Clin Invest 93:1288–1292PubMedCrossRef
Zurück zum Zitat Langeveld M, Ghauharali KJ, Sauerwein HP et al (2008) Type I Gaucher disease, a glycosphingolipid storage disorder, is associated with insulin resistance. Clin Endocrinol Metab 93:845–851 Langeveld M, Ghauharali KJ, Sauerwein HP et al (2008) Type I Gaucher disease, a glycosphingolipid storage disorder, is associated with insulin resistance. Clin Endocrinol Metab 93:845–851
Zurück zum Zitat Le NA, Gibson JC, Rubinstein A, Grabowski GA, Ginsberg HN (1988) Abnormalities in lipoprotein metabolism in Gaucher type 1 disease. Metabolism 37:240–245PubMedCrossRef Le NA, Gibson JC, Rubinstein A, Grabowski GA, Ginsberg HN (1988) Abnormalities in lipoprotein metabolism in Gaucher type 1 disease. Metabolism 37:240–245PubMedCrossRef
Zurück zum Zitat Lieberman J, Beutler E (1976) Elevation of serum angiotensin-converting enzyme in Gaucher’s disease. N Engl J Med 294:1442–1444PubMedCrossRef Lieberman J, Beutler E (1976) Elevation of serum angiotensin-converting enzyme in Gaucher’s disease. N Engl J Med 294:1442–1444PubMedCrossRef
Zurück zum Zitat Lorberboym M, Vallabhajosula S, Lipszyc H, Pastores G (1997) Scintigraphic evaluation of Tc-99 m-low-density lipoprotein (LDL) distribution in patients with Gaucher disease. Clin Genet 52:7–11PubMedCrossRef Lorberboym M, Vallabhajosula S, Lipszyc H, Pastores G (1997) Scintigraphic evaluation of Tc-99 m-low-density lipoprotein (LDL) distribution in patients with Gaucher disease. Clin Genet 52:7–11PubMedCrossRef
Zurück zum Zitat Lund-Katz S, Phillips MC (2010) High density lipoprotein structure—function and role in reverse cholesterol transport. Subcell Biochem 51:183–227PubMedCrossRef Lund-Katz S, Phillips MC (2010) High density lipoprotein structure—function and role in reverse cholesterol transport. Subcell Biochem 51:183–227PubMedCrossRef
Zurück zum Zitat Mistry PK, Deegan P, Vellodi A, Cole JA, Yeh M, Weinreb NJ (2009) Timing of initiation of enzyme replacement therapy after diagnosis of type 1 Gaucher disease: effect on incidence of avascular necrosis. Br J Haematol 147:561–570PubMedCrossRef Mistry PK, Deegan P, Vellodi A, Cole JA, Yeh M, Weinreb NJ (2009) Timing of initiation of enzyme replacement therapy after diagnosis of type 1 Gaucher disease: effect on incidence of avascular necrosis. Br J Haematol 147:561–570PubMedCrossRef
Zurück zum Zitat Mistry PK, Liu J, Yang M et al (2010) Glucocerebrosidase gene-deficient mouse recapitulates Gaucher disease displaying cellular and molecular dysregulation beyond the macrophage. Proc Natl Acad Sci 107(45):19473–10478 Mistry PK, Liu J, Yang M et al (2010) Glucocerebrosidase gene-deficient mouse recapitulates Gaucher disease displaying cellular and molecular dysregulation beyond the macrophage. Proc Natl Acad Sci 107(45):19473–10478
Zurück zum Zitat Mistry PK, Cappellini MD, Lukina C et al (2011) A reappraisal of Gaucher disease—diagnosis and disease mangement algorithms. Am J Hematol 86:110–115 Mistry PK, Cappellini MD, Lukina C et al (2011) A reappraisal of Gaucher disease—diagnosis and disease mangement algorithms. Am J Hematol 86:110–115
Zurück zum Zitat Nguyen AD, Pan CJ, Weinstein DA, Chou JY (2006) Increased scavenger receptor class B type I-mediated cellular cholesterol efflux and antioxidant capacity in the sera of glycogen storage disease type Ia patients. Mol Genet Metab 89:233–238PubMedCrossRef Nguyen AD, Pan CJ, Weinstein DA, Chou JY (2006) Increased scavenger receptor class B type I-mediated cellular cholesterol efflux and antioxidant capacity in the sera of glycogen storage disease type Ia patients. Mol Genet Metab 89:233–238PubMedCrossRef
Zurück zum Zitat Ober C, Tan Z, Sun Y et al (2008) Effect of variation in CHI3L1 on serum YKL-40, risk of asthma, and lung function. N Engl J Med 358:1682–1691PubMedCrossRef Ober C, Tan Z, Sun Y et al (2008) Effect of variation in CHI3L1 on serum YKL-40, risk of asthma, and lung function. N Engl J Med 358:1682–1691PubMedCrossRef
Zurück zum Zitat Pocovi M, Cenarro A, Civeira F et al (1998) Beta-glucocerebrosidase gene locus as a link for Gaucher's disease and familial hypo-alpha-lipoproteinaemia. Lancet 351:1919–1923PubMedCrossRef Pocovi M, Cenarro A, Civeira F et al (1998) Beta-glucocerebrosidase gene locus as a link for Gaucher's disease and familial hypo-alpha-lipoproteinaemia. Lancet 351:1919–1923PubMedCrossRef
Zurück zum Zitat Schoonhoven A, Rudensky B, Elstein D et al (2007) Monitoring of Gaucher patients with a novel chitotriosidase assay. Clin Chim Acta 381:136–139PubMedCrossRef Schoonhoven A, Rudensky B, Elstein D et al (2007) Monitoring of Gaucher patients with a novel chitotriosidase assay. Clin Chim Acta 381:136–139PubMedCrossRef
Zurück zum Zitat Sidransky E (2004) Gaucher disease: complexity in a "simple" disorder. Mol Genet Metab 83:6–15PubMedCrossRef Sidransky E (2004) Gaucher disease: complexity in a "simple" disorder. Mol Genet Metab 83:6–15PubMedCrossRef
Zurück zum Zitat Suzuki H, Kurihara Y, Takeya M et al (1997) A role for macrophage scavenger receptors in atherosclerosis and susceptibility to infection. Nature 386:292–296PubMedCrossRef Suzuki H, Kurihara Y, Takeya M et al (1997) A role for macrophage scavenger receptors in atherosclerosis and susceptibility to infection. Nature 386:292–296PubMedCrossRef
Zurück zum Zitat Taddei TH, Kacena KA, Yang M, Yang R, Malhotra A, Boxer M, Aleck KA, Rennert G, Pastores GM, Mistry PK (2009) The underrecognized progressive nature of N370S Gaucher disease and assessment of cancer risk in 403 patients. Am J Hematol 84:208–214PubMedCrossRef Taddei TH, Kacena KA, Yang M, Yang R, Malhotra A, Boxer M, Aleck KA, Rennert G, Pastores GM, Mistry PK (2009) The underrecognized progressive nature of N370S Gaucher disease and assessment of cancer risk in 403 patients. Am J Hematol 84:208–214PubMedCrossRef
Zurück zum Zitat Taddei TH, Dziura J, Chen S, Yang R, Hyogo H, Sullards C, Cohen DE, Pastores GM, Mistry PK (2010) High incidence of cholesterol gallstone disease type 1 Gaucher disease: characterizing the biliary phenotype of type 1 Gaucher disease. J Inherit Metab Dis 33:291–300PubMedCrossRef Taddei TH, Dziura J, Chen S, Yang R, Hyogo H, Sullards C, Cohen DE, Pastores GM, Mistry PK (2010) High incidence of cholesterol gallstone disease type 1 Gaucher disease: characterizing the biliary phenotype of type 1 Gaucher disease. J Inherit Metab Dis 33:291–300PubMedCrossRef
Zurück zum Zitat Tuchman LR, Suna H, Carr JJ (1956) Elevation of serum acid phosphatase in Gaucher’s disease. J Mt Sinai Hosp NY 23:227 Tuchman LR, Suna H, Carr JJ (1956) Elevation of serum acid phosphatase in Gaucher’s disease. J Mt Sinai Hosp NY 23:227
Zurück zum Zitat Vissers JP, Langridge JI, Aerts JM (2007) Analysis and quantification of diagnostic serum markers and protein signatures for Gaucher disease. Mol Cell Proteomics 6:755–766PubMedCrossRef Vissers JP, Langridge JI, Aerts JM (2007) Analysis and quantification of diagnostic serum markers and protein signatures for Gaucher disease. Mol Cell Proteomics 6:755–766PubMedCrossRef
Zurück zum Zitat von Eckardstein A, Nofer J, Assmann G (2001) High density lipoproteins and arteriosclerosis: role of cholesterol efflux and reverse cholesterol transport. Arterioscler Thromb Vasc Biol 21:13–27 von Eckardstein A, Nofer J, Assmann G (2001) High density lipoproteins and arteriosclerosis: role of cholesterol efflux and reverse cholesterol transport. Arterioscler Thromb Vasc Biol 21:13–27
Zurück zum Zitat Weinreb N, Taylor J, Cox T, Yee J, vom Dahl S (2008) A benchmark analysis of the achievement of therapeutic goals for type 1 Gaucher patients treated with imiglucerase. Am J Hematol 83:890–895PubMedCrossRef Weinreb N, Taylor J, Cox T, Yee J, vom Dahl S (2008) A benchmark analysis of the achievement of therapeutic goals for type 1 Gaucher patients treated with imiglucerase. Am J Hematol 83:890–895PubMedCrossRef
Zurück zum Zitat Xu YH, Quinn B, Witte D, Grabowski GA (2003) Viable mouse models of acid beta glucosidase deficiency in Gaucher disease. Am J Pathol 163:2093–2101PubMedCrossRef Xu YH, Quinn B, Witte D, Grabowski GA (2003) Viable mouse models of acid beta glucosidase deficiency in Gaucher disease. Am J Pathol 163:2093–2101PubMedCrossRef
Zurück zum Zitat Yvan-Charvet L, Pagler T, Gautier EL et al (2010) ATP-binding cassette transporters and HDL suppress hematopoietic stem cell proliferation. Science 328:1689–1693PubMedCrossRef Yvan-Charvet L, Pagler T, Gautier EL et al (2010) ATP-binding cassette transporters and HDL suppress hematopoietic stem cell proliferation. Science 328:1689–1693PubMedCrossRef
Zurück zum Zitat Zimran A, Kay A, Gelbart T, Saven, Beutler E (1992) Gaucher disease. Clinical, laboratory, radiologic, and genetic features of 53 patients. Med Baltim 71:337–353CrossRef Zimran A, Kay A, Gelbart T, Saven, Beutler E (1992) Gaucher disease. Clinical, laboratory, radiologic, and genetic features of 53 patients. Med Baltim 71:337–353CrossRef
Metadaten
Titel
Evaluation of high density lipoprotein as a circulating biomarker of Gaucher disease activity
verfasst von
Philip Stein
Ruhua Yang
Jun Liu
Gregory M. Pastores
Pramod K. Mistry
Publikationsdatum
01.04.2011
Verlag
Springer Netherlands
Erschienen in
Journal of Inherited Metabolic Disease / Ausgabe 2/2011
Print ISSN: 0141-8955
Elektronische ISSN: 1573-2665
DOI
https://doi.org/10.1007/s10545-010-9271-7

Weitere Artikel der Ausgabe 2/2011

Journal of Inherited Metabolic Disease 2/2011 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.